Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid is a synthetic small molecule belonging to the benzoic acids class. It has been studied as a ligand for the peroxisome proliferator–activated receptor gamma (PPARγ), a nuclear receptor involved in lipid metabolism, glucose homeostasis, and adipogenesis. Structural studies have shown this compound binds to and activates PPARγ, suggesting potential utility as an experimental tool or lead compound for metabolic disease research. There are no approved clinical indications or marketed products containing this molecule[5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid.